Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China
03/09/2026 05:01
BRIEF-Eisai Co., Ltd. - Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China Sept 3 (Reuters) - Eisai Co., Ltd. 4523.T:
EISAI CO., LTD. - LEQEMBI (LECANEMAB) SUBCUTANEOUS FORMULATION AS AN INITIATION TREATMENT FOR EARLY ALZHEIMER'S DISEASE APPROVED IN CHINA
Source text: ID:nTSuc81b1c
Further company coverage: 4523.T
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China